Hepatitis B Virus Reactivation in a Surface Antigen-negative and Antibody-positive Patient after Rituximab Plus CHOP Chemotherapy / Journal of the Korean Cancer Association, 대한암학회지
Cancer Research and Treatment
;
: 36-38, 2008.
Article
in English
| WPRIM
| ID: wpr-65925
ABSTRACT
Rituximab is a monoclonal antibody that targets B-lymphocytes, and it is widely used to treat non-Hodgkin's lymphoma. However, its use has been implicated in HBV reactivation that's related with the immunosuppressive effects of rituximab. Although the majority of reactivations occur in hepatitis B carriers, a few cases of reactivation have been reported in HBsAg negative patients. However, reactivation in an HBsAg negative/ HBsAb positive patient after rituximab treatment has never been reported in Korea. We present here an HBsAg-negative/HBsAb-positive 66-year-old female who displayed reactivation following rituximab plus CHOP chemotherapy for diffuse large B-cell lymphoma. While she was negative for HBsAg at diagnosis, her viral status was changed at the time of relapse as follows HBsAg positive, HBsAb negative, HBeAg positive, HBeAb negative and an HBV DNA level of 1165 pg/ml. Our observation suggests that we should monitor for HBV reactivation during rituximab treatment when prior HBV infection or occult infection is suspected, and even in the HBsAg negative/HBsAb positive cases.
Full text:
Available
Index:
WPRIM (Western Pacific)
Main subject:
Organothiophosphorus Compounds
/
Recurrence
/
Lymphoma, Non-Hodgkin
/
DNA
/
B-Lymphocytes
/
Hepatitis B virus
/
Lymphoma, B-Cell
/
Antibodies, Monoclonal, Murine-Derived
/
Rituximab
/
Hepatitis
Limits:
Aged
/
Female
/
Humans
Country/Region as subject:
Asia
Language:
English
Journal:
Cancer Research and Treatment
Year:
2008
Type:
Article
Similar
MEDLINE
...
LILACS
LIS